Minerva Urology and Nephrology最新文献

{"title":"Robot-assisted artificial urinary sphincter revision in \"non-neurogenic\" stress urinary incontinence in female patients: surgical technique and outcomes.","authors":"Mariela Corrales, Paolo Geretto, Martina Moriconi, Maria L Gallo, Sabrina DE Cillis, Veronique Phé","doi":"10.23736/S2724-6051.25.06123-3","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06123-3","url":null,"abstract":"<p><strong>Background: </strong>Robot-assisted artificial urinary sphincter (AUS) implantation is a suitable option for the treatment of severe stress urinary incontinence (SUI) in female patients. However, to the best of our knowledge, any report of robotic AUS revision in case of recurrent SUI is available. The present study aims to provide the outcomes of a cohort of female patients subjected to robot-assisted AUS revision at a single tertiary referral center and to describe the surgical technique.</p><p><strong>Methods: </strong>The main surgical steps are the following: through robotic technique, the AUS reservoir and urethral cuff are found by following the connection tubes. The reservoir and the activating pump are then removed, and the urethral cuff is opened. A measuring tape is used to obtain the correct size of the bladder neck and to choose the correct new cuff, which is then placed. The reservoir is replaced, and the connection tubes are exteriorized. Finally, a subcutaneous passage towards the right labia majora is obtained and the connections are closed. The outcomes of a retrospective cohort of female patients subjected to robotic AUS revision according to the described technique are also provided.</p><p><strong>Results: </strong>Four patients were included. The median age was 63 (51-76 years); the median time to revision was 12 years (5-16 years). Median operative time was 160.5 (130-185 minutes). The reason for the AUS revision was a mechanical failure of the device in all cases. Any intra-operative or severe postoperative complication (Clavien-Dindo ≥3) was observed. After AUS activation at 4 weeks, all patients were dry.</p><p><strong>Conclusions: </strong>Robotic AUS revision in female patients is a feasible and safe technique and can give excellent functional outcomes.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"408-412"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approach.","authors":"Matteo Ferro, Octavian S Tataru, Giuseppe Fallara, Cristian Fiori, Matteo Manfredi, Francesco Claps, Rodolfo Hurle, Nicolò M Buffi, Giovanni Lughezzani, Massimo Lazzeri, Achille Aveta, Savio D Pandolfo, Biagio Barone, Felice Crocetto, Pasquale Ditonno, Giuseppe Lucarelli, Francesco Lasorsa, Giuseppe Carrieri, Gian M Busetto, Ugo G Falagario, Francesco Del Giudice, Martina Maggi, Francesco Cantiello, Marco Borghesi, Carlo Terrone, Pierluigi Bove, Alessandro Antonelli, Alessandro Veccia, Andrea Mari, Stefano Luzzago, Raul Gherasim, Ciprian Todea-Moga, Andrea Minervini, Gennaro Musi, Francesco A Mistretta, Roberto Bianchi, Marco Tozzi, Francesco Soria, Paolo Gontero, Michele Marchioni, Letizia M Janello, Daniela Terracciano, Giorgio I Russo, Luigi Schips, Sisto Perdonà, Riccardo Autorino, Michele Catellani, Chiara Sighinolfi, Emanuele Montanari, Savino M DI Stasi, Francesco Porpiglia, Bernardo Rocco, Ottavio de Cobelli, Roberto Contieri","doi":"10.23736/S2724-6051.24.05876-2","DOIUrl":"10.23736/S2724-6051.24.05876-2","url":null,"abstract":"<p><strong>Background: </strong>Approximately 70% of bladder cancer is diagnosed as non-muscle invasive (NMIBC) and inflammation is known to impact the oncological outcomes. Adjuvant intravesical BCG in intermediate/high risk can lower recurrence and progression. The efficacy of intravesical BCG can be impacted by smoking effects on systemic inflammation.</p><p><strong>Methods: </strong>Our retrospective, multicenter study with data from 1.313 NMIBC patients aimed to assess the impact of smoking and the systemic inflammatory status on BCG response in T1G3 bladder cancer, using a machine-learning CART based algorithm.</p><p><strong>Results: </strong>In a median of 50-month follow-up (IQR 41-75), 344 patients experienced progression to muscle invasive or metastatic disease and 65 died due to bladder cancer. A CART algorithm has been employed to stratify patients in three prognostic clusters using smoking status, LMR (lymphocytes to monocytes ratio), NLR (neutrophil-to-lymphocyte ratio) and PLR (platelet-to-lymphocyte ratio) as variables. Cox regression models revealed a 1.5-fold (HR 1.66, 95%, CI 1.20-2.29, P=0.002) and three-fold (HR 2.99, 95% CI 2.08-4.30, P<0.001) risk of progression, in intermediate and high risk NMIBC respectively, compared to the low-risk group. The model's concordance index was 0.66.</p><p><strong>Conclusions: </strong>Our study provides an insight into the influence of smoking on inflammatory markers and BCG response in NMIBC patients. Our machine-learning approach provides clinicians a valuable tool for risk stratification, treatment, and decision-making. Future research in larger prospective cohorts is required for validating these findings.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"338-346"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YAU Renal Cancer SPOTLIGHT: the promise of molecular imaging to decrypt the renal tumors histological spectrum.","authors":"Savio D Pandolfo, Riccardo Bertolo, Stijn Muselaers, Selcuk Erdem, Michele Marchioni, Riccardo Campi, Daniele Amparore","doi":"10.23736/S2724-6051.25.06499-7","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06499-7","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"413-416"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YAU renal cancer SPOTLIGHT: the understated challenge of tumor rupture during robotic partial nephrectomy.","authors":"Riccardo Bertolo, Riccardo Campi, Daniele Amparore","doi":"10.23736/S2724-6051.25.06509-7","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06509-7","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"417-421"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DCOM: a 3D virtual imaging-based nephrometry scoring system for robot-assisted partial nephrectomy.","authors":"Zhengsheng Liu, Tao Wang, Zongkai Zhang, Wei Li, Xuegang Wang, Kaiyan Zhang, Zhun Wu, Zhipeng Li, Zhongjie Zhao, Chaohao Miao, Yu Luo, Bin Chen, Jinchun Xing","doi":"10.23736/S2724-6051.25.06002-1","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06002-1","url":null,"abstract":"<p><strong>Background: </strong>The aim of this paper was to establish a new surgical difficulty scoring system of robot-assisted partial nephrectomy (RAPN) based on three-dimensional (3D) virtual imaging.</p><p><strong>Methods: </strong>We collected data from the patients subjected to robot-assisted surgery. 296 presented complete demographic and clinical data including RAPN and robot-assisted radical nephrectomy (RARN). Researchers used preoperative enhanced CT or MRI image data, and 3D image reconstruction, 4 independent variables were assessed: diameter of tumor inside kidney (D); compression of the renal segmental vessels; occupation of the renal sinus; mass exophytic rate (DCOM). DCOM score was then used to aid surgical decision-making and guide surgical strategy planning. The predictive values of DCOM score were analyzed using a multinomial logistic regression mode.</p><p><strong>Results: </strong>We confirmed that DCOM score as predictor of surgical outcome significantly outperformed the other common predictors used (RENAL and PADUA score).</p><p><strong>Conclusions: </strong>The surgical difficulty scoring system (DCOM scoring system) of partial nephrectomy (PN) based on 3D virtual imaging-based nephrometry system could provide a basis for the formulation of preoperative surgical strategy, but further verification is needed.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"308-319"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual function outcomes in men undergoing minimal invasive ablative techniques for prostate cancer: a ESRU/YAU urotech systematic review and pooled analysis.","authors":"Federico Piramide, Alessandro Veccia, Lazaros Tzelves, Sven Nikles, Luis E Ortega Polledo, Luigi Nocera, Adrian Khelif, Leo Dumbovic, Lazaros Lazarou, Edoardo Cisero, Alberto Quarà, Andrea Sterrantino, Ugo Falagario, Pietro Piazza, Loic Baekealndt, Diego M Carrion, Juan Gomez Rivas, Giovanni Cacciamani, Enrico Checcucci","doi":"10.23736/S2724-6051.25.06007-0","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06007-0","url":null,"abstract":"<p><strong>Introduction: </strong>In the latest years the advent of minimally invasive focal treatment for prostate cancer (PCa) has gained a wide diffusion. Different platforms and sources of energy have been developed (HIFU, cryotherapy, focal brachytherapy…) and reported to be able to effectively treat PCa with minimal impact on sexual function. The aim of this systematic review is to summarize, evaluate and compare the impact of these focal therapies on the sexual function (erectile and ejaculatory function) of men harboring low to intermediate risk PCa.</p><p><strong>Evidence acquistion: </strong>A systematic literature search was conducted in October 2022 and updated in August 2024 using Medline (via PubMed), Embase (via Ovid), Scopus, and Web of Science (registered on PROSPERO as CRD42022370237). The search strategy used PICO criteria and article selection was conducted following the PRISMA guidelines. The risk of bias and the quality of the articles included were assessed. A dedicated data extraction form was used to collect the data of interest.</p><p><strong>Evidence synthesis: </strong>Overall, our electronic search identified 4465 papers, 96 of which ultimately met the inclusion criteria and thus were included in the analysis. Among them, 87 were single arm studies, eight were comparative studies, whilst only 1 was a randomized prospective study. Overall, 6244 patients were evaluated (2318 HIFU, 2034 focal cryoablation, 1194 irreversible electroporation [IRE], 346 focal laser ablation [FLA], 147 high-dose brachytherapy [HDB], 247 Vascular photodynamic therapy [VPT], 21 focal microwave ablation [FMA], 151 low-dose brachytherapy [LDB], 10 focal bipolar radiofrequency ablation [FBRA] and 22 trans-urethral ultrasound ablation [TULSA]). The most reported measure of sexual function was IIEF-5, with baseline scores ranging from 16.2 (IRE) to 22.35 (VPT). At 12 months post-treatment, VPT and high-dose brachytherapy had the highest IIEF-5 scores (20.01 and 19.90, respectively), while cryotherapy, low-dose brachytherapy, and HIFU had the lowest (14.08, 14.94, and 15.40, respectively). Ejaculatory function was underreported, with only two studies assessing its preservation after HIFU. Safety analysis showed an overall complication rate of 21%, with major complications occurring in 1.4% of cases.</p><p><strong>Conclusions: </strong>FT offers a promising balance between oncologic control and functional preservation in low- to intermediate-risk PCa. However, significant variability in FT modalities, ablation strategies (focal vs. hemigland vs. zonal), and outcome assessment methods limits direct comparisons. Future prospective studies with standardized protocols and long-term follow-up are essential to optimize patient selection and improve functional outcomes.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"285-297"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overactive bladder: results from patients treated by hyaluronic acid-chondroitin sulphate therapy.","authors":"Roberto Falabella, Simone Morra, Luigi Milella, Sabrina LA Falce, Giuseppe DI Fino, Saveriano Lioi, Franco C Ponti, Aldo DI Fazio, Vito Mancini, Felice Crocetto, Vincenzo F Caputo, Giuseppe Carrieri","doi":"10.23736/S2724-6051.24.05786-0","DOIUrl":"10.23736/S2724-6051.24.05786-0","url":null,"abstract":"<p><strong>Background: </strong>Overactive bladder (OAB) is a chronic condition. This study was prompted by the need to fill the gap between medical treatment and advanced therapies allowing improvement in Quality of Life. The aim of the current study was to evaluate the association between treatment type (Ialuril^®; IBSA Farmaceutici, Lodi, Italy; in combination with antimuscarinic or alone after drop-out of antimuscarinic, relative to antimuscarinic alone treatment) and functional outcomes (number of micturitions, pelvic pain, urinary incontinence, nocturia, urgency).</p><p><strong>Methods: </strong>Of all patients newly diagnosed (January 2016 - January 2022) with OAB syndrome, we retrospectively identified 150 patients. They harbored three groups of 50 patients each: group 1 (antimuscarinic drug), group 2 (antimuscarinic drug + hyaluronic acid-chondroitin sulphate [HA-CS]), group 3 (antimuscarinic dropout patients). Univariable linear and logistic regression models were fitted for number and rates of incontinence, urgency, pelvic pain, nocturia, respectively.</p><p><strong>Results: </strong>A significant mean reduction of 1.5 micturition (P=0.02) was recorded in group 2 compared to group 1. Conversely, no statistically significant mean difference was recorded in group 3 compared to group 1. Regarding pelvic pain, both group 2 and group 3 were associated with lower rate of pelvic pain (P<0.001). Regarding urgency, a statistically significant protective OR was recorded for group 2 (OR=0.39; P=0.04), compared to group 1.</p><p><strong>Conclusions: </strong>The combination therapy was associated with symptom improvement in antimuscarinic naïve OAB patients. Conversely in antimuscarinic dropped-out patients only pelvic pain improved with the HS-CA. No statistically significant differences were recorded for other functional outcomes, such as incontinence and nocturia.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"375-382"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial penectomy with glans reconstruction: technical modification.","authors":"Guglielmo Mantica, Benedetta Col, Federica Balzarini, Giorgia Granelli, Tommaso Saccucci, Carlo Terrone","doi":"10.23736/S2724-6051.25.06466-3","DOIUrl":"10.23736/S2724-6051.25.06466-3","url":null,"abstract":"","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"441-442"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous ablation of renal tumors in patients with a solitary kidney: medium- to long-term outcomes.","authors":"María E Perez Montilla, Pedro B García Jurado, Enrique Gómez Gómez, Sara Barranco Acosta, María S Lombardo Galera, Pablo J Campos Hernández, Juan J Espejo Herrero","doi":"10.23736/S2724-6051.25.06010-0","DOIUrl":"https://doi.org/10.23736/S2724-6051.25.06010-0","url":null,"abstract":"<p><strong>Background: </strong>This work aims to evaluate safety, medium- and long-term efficacy, and renal function outcomes of percutaneous ablation (PA) of renal masses in patients with a solitary kidney (PSK).</p><p><strong>Methods: </strong>This retrospective, single-center study enrolled 53 consecutive tumors in 33 PSK from April 2004 to October 2021. Renal tumors were treated with image-guided PA. Clinical data, radiographic characteristics, and complications at 30 days were collected. Follow-up involved clinical and radiological imaging to assess technical efficacy and recurrence. Serum creatine and glomerular filtration rate (GFR) for measuring renal function were determined at baseline, 12 months, and end of follow-up.</p><p><strong>Results: </strong>Thirty-three PSK (21 male) aged 35 to 85 years were treated for 53 renal tumors. The mean size was 25.8 mm (IQR 17.5-30). The mean RENAL and PADUA scores were 6.3 (IQR 4.5-8) and 8 (IQR 6-10). Nine complications (Clavien-Dindo grade I, II, III) occurred in 42 sessions. RENAL and PADUA scores and endophytic localization were significantly associated with complications. Technical efficacy after one session was 88.7%; The mean follow-up time was 45.8 months (IQR 18-48). There were five local recurrences (10%) at a mean of 28 months (IQR 17-40). GFR declined 14.8% at 12 months. GFR declines were 13 mL/min/m² in patients with one lesion and 26.9 mL/min/m² with two or more (P=0.048). Two patients required hemodialysis.</p><p><strong>Conclusions: </strong>PA is a safe treatment option in PSK that provides good long-term cancer control and minimal clinical impact on postoperative renal function.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 3","pages":"347-355"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of antibiotic treatment duration for preoperative asymptomatic bacteriuria, during urological surgery, on postoperative infectious complications: results from the multicentric TOCUS cohort.","authors":"Humphrey Robin, Stessy Kutchukian, Pierre Bigot, Marc Françot, Stéphane de Vergie, Jérôme Rigaud, Mathilde Chapuis, Laurent Brureau, Camille Jousseaume, Omar Karray, Fares T Kosseifi, Aurélien Descazeaud, Harrison-Junior Asare, Maxime Gaullier, Baptiste Poussot, Thibault Tricard, Shahed Borojeni, Bastien Gondran-Tellier, Michael Baboudjian, Éric Lechevallier, Pierre-Olivier Delpech, Elias Ayoub, Héloïse Ducousso, Simon Bernardeau, Aurélien Dinh, Franck Bruyère, Maxime Vallée","doi":"10.23736/S2724-6051.24.05725-2","DOIUrl":"10.23736/S2724-6051.24.05725-2","url":null,"abstract":"<p><strong>Background: </strong>According to the European guidelines, any urological surgery breaching the mucosa requires preoperative screening and antibiotic treatment of any asymptomatic bacteriuria (ABU).</p><p><strong>Methods: </strong>The aim of this study was to determine whether the preoperative antibiotic treatment duration of ABU in urological surgery impact postoperative infectious complications. National multicenter, retrospective study including all consecutive patients screened for ABU before urologic surgery in 10 centers from 1^st April 2019 to April 2023. The primary endpoint was all postoperative infectious complications occurring within 30 days after surgery. Short antibiotic treatment (SAT) of ABU was defined by 5- day regimen or less. Long antibiotic treatment (LAT) was defined by duration longer than 5 days.</p><p><strong>Results: </strong>Among the 2389 patients included, 839 (35.1%) patients had positive urine culture (UC), of whom 546 (65%) had positive mono or bimicrobial UC and 292 (34.8%) polymicrobial UC. There were 106 (4.4%) postoperative infectious complications occurring within 30 days including 62 (58.5%) in the positive UC group. In the positive UC group, 336 (40%) had received SAT, 261 (31.1%) LAT and 231 (27.5%) had not received any treatment. The 30-day surgery-related infection rates were 8.3%, 6.1% and 7.36% respectively. There was no statistical difference between SAT versus LAT in the univariate analysis (P=0.6) or in the multivariate analysis OR 1.97 [0.37, 1.86] (P=0.06).</p><p><strong>Conclusions: </strong>Our results found no association between antibiotic treatment duration and urinary infectious complication among patients with preoperative ABU who undergo urological surgery. These results need a RCT to be confirmed.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"365-374"},"PeriodicalIF":4.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}